No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
US OptionsDetailed Quotes
AVXL250117P14000
- 3.05
- 0.000.00%
15min DelayClose Jan 10 16:00 ET
0.00High0.00Low
3.05Open3.05Pre Close0 Volume78 Open Interest14.00Strike Price0.00Turnover218.80%IV2.49%PremiumJan 17, 2025Expiry Date2.77Intrinsic Value100Multiplier4DDays to Expiry0.28Extrinsic Value100Contract SizeAmericanOptions Type-0.7894Delta0.1080Gamma3.51Leverage Ratio-0.0884Theta-0.0013Rho-2.77Eff Leverage0.0035Vega
Intraday
- 5D
- Daily
News
Express News | Anavex Life Sciences Corp: Blarcamesine Exhibited a Favorable Safety Profile With No Treatment-Related Deaths
Express News | Anavex Life Sciences Corp: Topline Attention-Ad Trial: Patients Showed Improved Cognition and Function Over Three Years
Express News | New Phase Iib/III Clinical Data Demonstrates Over Three Years of Continuous Treatment With Oral Blarcamesine to Significantly Benefit Early Alzheimer’s Disease Patients
Anavex Life Sciences (AVXL) Alzheimer Treatment Sends the Stock to New Heights
Anavex Life Sciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Are Medical Stocks Lagging Anavex Life Sciences (AVXL) This Year?